- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03408561
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
The Use of Social Media Listening for Targeted Recruitment of Twitter Users in LA County in Cancer Trials Compared to Historic Recruitment Data: A Mixed-Methods Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Examine the feasibility (acceptance among University of Southern California [USC] Norris study team members and Twitter users in Los Angeles [LA] county) of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.
II. Gain preliminary data on the impact (i.e., numbers recruited versus projected accrual compared to historic recruitment) of targeted social media listening (SML) as a tool for enhancing recruitment to cancer trials among Twitter users in LA county.
III. Estimate the effect size of the number of people enrolled associated with the use of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials.
OUTLINE:
Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- TRIAL INCLUSION:
- Focus on one of the following disease categories: non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma
- Be a phase 1 trial in expansion, phase 2, or 3
- Be interventional trials
- Recruit in English
- Be Institutional Review Board (IRB)-approved and open to accrual at USC Norris
- Recruit for at least 9 months at the point of enrollment
- Set monthly accrual target >= 1/ and annual accrual target >= 12
- PATIENT INCLUSION:
- Will include all prospective trial participants in this study that come from Twitter in response of our SM recruitment interventions, provided they meet the specific trial's eligibility criteria
Exclusion Criteria:
- TRIAL EXCLUSION:
- Phase 1 trials in dose escalation
- PATIENT EXCLUSION:
- Persons who do not meet the eligibility criteria of any of the trials open to accrual will be excluded from participation, and persons who may be eligible (e.g., disease/histology, stage, prior treatment) but do not meet additional trial-specific requirements such as insurance or allergy to drug)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Health Services Research (message via Twitter)
Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter.
Patients are then contacted for recruitment into a clinical trial.
|
Ancillary studies
Receive message via Twitter
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
User acceptance and satisfaction with social media (SM) as a recruitment method
Time Frame: Up to 14 months
|
A questionnaire will be used assess the acceptance of and satisfaction with SM recruitment method among University of Southern California (USC) Norris study team members and Twitter users in Los Angeles (LA) county.
|
Up to 14 months
|
|
Accrual rate
Time Frame: Up to 14 months
|
To be determined by comparing monthly actual versus (vs.) projected rate of recruitment for the trial disease groups (i.e., non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma) using generalized estimating equations, accounting for intra-disease random effects and trends across the 12 months (9 months exposure per trial).
These results will then be put into context of the historic recruitment for these diseases at the center.
|
Up to 14 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thomas Buchanan, MD, University of Southern California
Publications and helpful links
General Publications
- Reuter K, Angyan P, Le N, Buchanan TA. Using Patient-Generated Health Data From Twitter to Identify, Engage, and Recruit Cancer Survivors in Clinical Trials in Los Angeles County: Evaluation of a Feasibility Study. JMIR Form Res. 2021 Nov 26;5(11):e29958. doi: 10.2196/29958.
- Reuter K, Angyan P, Le N, MacLennan A, Cole S, Bluthenthal RN, Lane CJ, El-Khoueiry AB, Buchanan TA. Monitoring Twitter Conversations for Targeted Recruitment in Cancer Trials in Los Angeles County: Protocol for a Mixed-Methods Pilot Study. JMIR Res Protoc. 2018 Sep 25;7(9):e177. doi: 10.2196/resprot.9762.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Genital Neoplasms, Male
- Breast Diseases
- Prostatic Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Breast Neoplasms
- Prostatic Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma
Other Study ID Numbers
- 0S-17-7 (OTHER: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2017-02145 (REGISTRY: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Novartis PharmaceuticalsBristol-Myers SquibbTerminatedNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaItaly, Singapore, Australia, China, Germany, South Korea, Japan
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Lymphoplasmacytic... and other conditionsUnited States, Canada
-
IGM Biosciences, Inc.ADC Therapeutics S.A.TerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Juno Therapeutics, a Subsidiary of CelgeneCompletedFollicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell LymphomaUnited States
-
Lymphoma Study AssociationCompletedLymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaFrance
-
Emory UniversityNational Cancer Institute (NCI); AstraZenecaRecruitingMantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Lymphoproliferative Disorder | Indolent Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
Clinical Trials on Survey Administration
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedSarcoma | Breast Carcinoma | Head and Neck CarcinomaUnited States
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMalignant Vascular NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMelanoma | COVID-19 InfectionUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)WithdrawnMelanoma | Breast Carcinoma | Lung Carcinoma | Colorectal Carcinoma | Community Practice | Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Institutes of Health (NIH)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)WithdrawnCommunity Practice | StaffUnited States